

## **Clinical Policy: Brigatinib (Alunbrig)**

Reference Number: CP.PHAR.342

Effective Date: 07.17.17

Last Review Date: 05.21

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

Brigatinib (Alunbrig<sup>®</sup>) is a kinase inhibitor.

### **FDA Approved Indication(s)**

Alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Alunbrig is **medically necessary** when the following criteria are met:

#### **I. Initial Approval Criteria**

##### **A. Non-Small Cell Lung Cancer (must meet all):**

1. Diagnosis of recurrent, advanced or metastatic NSCLC;
2. Prescribed by or in consultation with an oncologist;
3. Age  $\geq$  18 years;
4. Disease is ALK positive;
5. For Alunbrig requests, member must use generic brigatinib, if available, unless contraindicated or clinically significant adverse effects are experienced;
6. Request meets one of the following (a or b):\*
  - a. Dose does not exceed 180 mg per day;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

##### **Approval duration:**

**Medicaid/HIM** – 6 months

**Commercial** – Length of Benefit

##### **B. Inflammatory Myofibroblastic Tumor (off-label) (must meet all):**

1. Diagnosis of inflammatory myofibroblastic tumor (IMT; a soft tissue sarcoma);
2. Prescribed by or in consultation with an oncologist;
3. Age  $\geq$  18 years;
4. Disease is ALK positive;

**CLINICAL POLICY**  
**Brigatinib**

5. For Alunbrig requests, member must use generic brigatinib, if available, unless contraindicated or clinically significant adverse effects are experienced;
6. Request meets one of the following (a or b):\*
  - a. Dose does not exceed 180 mg per day;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration:**

**Medicaid/HIM** – 6 months

**Commercial** – Length of Benefit

**C. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy****A. All Indications in Section I (must meet all):**

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Alunbrig for NSCLC or IMT and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. For Alunbrig requests, member must use generic brigatinib, if available, unless contraindicated or clinically significant adverse effects are experienced;
4. If request is for a dose increase, request meets one of the following (a or b):\*
  - a. New dose does not exceed 180 mg per day.
  - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration:**

**Medicaid/HIM** - 12 months

**Commercial** – Length of Benefit

**B. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
**Approval duration: Duration of request or 6 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

## CLINICAL POLICY

### Brigatinib

#### III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

#### IV. Appendices/General Information

##### *Appendix A: Abbreviation/Acronym Key*

ALK: anaplastic lymphoma kinase                      NCCN: National Comprehensive Cancer Network  
 FDA: Food and Drug Administration  
 IMT: inflammatory myofibroblastic tumor        NSCLC: non-small cell lung cancer

##### *Appendix B: Therapeutic Alternatives*

Not applicable

##### *Appendix C: Contraindications/Boxed Warnings*

None reported

#### V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
ALK-positive NSCLC	90 mg PO QD for the first 7 days; if tolerated, increase to 180 mg PO QD	180 mg/day

#### VI. Product Availability

Tablets: 30 mg, 90 mg, 180 mg

#### VII. References

1. Alunbrig Prescribing Information. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; May 2020. Available at: [www.alunbrig.com](http://www.alunbrig.com). Accessed January 12, 2021.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at [www.nccn.org](http://www.nccn.org). Accessed January 12, 2021.
3. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer Version 2.2021. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Accessed January 12, 2021.
4. National Comprehensive Cancer Network Guidelines. Central Nervous System Cancers Version 3.2020. Available at [www.nccn.org](http://www.nccn.org). Accessed January 12, 2021.
5. National Comprehensive Cancer Network Guidelines. Soft Tissue Sarcoma Version 1.2021. Available at [www.nccn.org](http://www.nccn.org). Accessed January 12, 2021.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created.	05.17	07.17

**CLINICAL POLICY**  
**Brigatinib**

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2018 annual review: no significant changes; combined policies for Medicaid and Commercial lines of business; added age; approval duration for commercial changed to length of benefit; summarized NCCN and FDA approved uses for improved clarity; added specialist involvement in care; added continuity of care statement; references reviewed and updated.	02.13.18	05.18
2Q 2019 annual review: NCCN designation of advanced added to NSCLC; Xalkori and Zykadia trials removed per NCCN recommendation of Alunbrig as first-line therapy for ALK positive NSCLC; references reviewed and updated.	02.19.19	05.19
2Q 2020 annual review: added HIM line of business; modified continued approval duration from 6 to 12 months; references reviewed and updated.	02.11.20	05.20
RT4: updated FDA Approved Indication(s) section to reflect revised indication for use as a first-line therapy in ALK+ NSCLC; removed limitation of use.	06.02.20	
2Q 2021 annual review: added NCCN supported use in ALK positive IMT; oral oncology generic redirection language added; revised reference to HIM off-label use policy from HIM.PHAR.21 to HIM.PA.154; references reviewed and updated.	01.12.21	05.21

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

## CLINICAL POLICY

### Brigatinib

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.